Milan-based Dompé Farmaceutici, a biopharmaceutical company, has invested in the US$54m Series A funding round of UK-based biopharmaceutical company, Engitix. The companies have also signed a multi-year, multi-programme strategic R&D collaboration to support identification of new treatments against fibrosis and liver-associated solid tumours. Dompé will provide access to its Exscalate AI drug discovery platform and…
Home Healthcare Markets International News Italy: Dompé signs strategic collaboration with Engitix and joins Series A